Functional study of TNF-α promoter polymorphisms: Literature review and meta-analysis

European Cytokine Network

Volumn 22, Issue 2, 2011, Pages 88-102

  Mekinian, Arsene ^a   Tamouza, Ryad ^b   Pavy, Stephan ^c   Gestermann, Nicolas ^a   Ittah, Marc ^a   Mariette, Xavier ^a,c   Miceli Richard, Corinne ^a,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Functional study; Haplotypes; Review; Single nucleotide polymorphisms; TNF

Indexed keywords

LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

BLOOD LEVEL; CANCER CELL CULTURE; CELL CULTURE; CELL ISOLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HAPLOTYPE; HUMAN; META ANALYSIS; MONOCYTE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

HAPLOTYPES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79961009652     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2011.0285     Document Type: Review

References (56)

1. Brennan M, McIlnnes M. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Investigation 2008; 118: 3537-44.
2. Miceli-Richard C, Comets E, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008; 67: 478-84.
3. Bayley JP, Ottenhoff THM, Verweij CL. Is there a future for TNF-α promoter polymorphism? Genes Immun 2004; 5: 315-29.
4. Kaijzel EL, Bayley JP, Smith L Van de Linde P Bakker AM Verweij CL. Allele-specific quantification of tumour necrosis factor alpha transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2001; 2: 135-44.
5. Knight J, Keating B, Rockett K, Kwiatkowski D. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nature Genetics 2003; 33: 469-75.
6. Bero L, Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995; 274: 1935-8.
7. Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P. Association between the level of circulating bioactive tumour necrosis factor α and the TNF-α gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor inhibitor. Arthritis Rheum 2008; 58: 1258-63.
8. O'Dwyer M. J, Mankan AK, Ryan AW, et al. Characterization of tumour necrosis factor-alpha genetic variants and mRNA expression in patients with severe sepsis. Intern J Immunogenetics 2008; 35: 279-85.
9. He B, Navikas V, Lundahl J, Soderstrom M, Hillert J. Tumor necrosis factor alpha 308 alleles in multiple sclerosis and optic neuritis. J Neuromimmunol 1995; 63: 143-7.
10. Baseggio L, Bienvenu J, Charlot C, Picollet J, Felman P, Salles G. Higher LPS-induced TNF-alpha mRNA levels in peripheral blood cells from non-Hodgkin's lymphoma patients. Exp Hematol 2001; 29: 330-9.
11. Lu M, Tung C, Huang Y, Yu H, Lai N. Higher LPS-stimulated TNF-alpha mRNA levels in peripheral blood from Chinese ankylosing spondylitis patients with -308G/A polymorphism: association with distinct A33/B58/CW10 haplotypes. Rheumatol Int 2008; 29: 189-95.
12. Oregon-Romero E,Vazquez-Del Mercado M, Ruiz-Quezada S, et al. TNF- -308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-α. J Investig Med 2008; 56: 937-43.
13. Stuber F, Udalova IA, Book M, Drutskaya LN, Kuprash LN, Nedospasov SA. -308 tumor necrosis factor polymorphism is not associated with survival in sepsis and is unrelated to LPS inducibility of the human TNF- promoter. J Inflamm 1996; 46: 42-50.
14. Kroeger K, Carville K, Abraham L. The -308 tumor necrosis factor promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-9.
15. Bailey JP, de Rooji H, Huizinga T, Verweij C. Functional analysis of linker-scan mutants spanning the -376, -308, -244 and -238 polymorphic sites of the TNF-alpha promoter. Cytokine 2001; 14: 316-23.
16. Kroeger K, Steer J, Joyce D, Abraham L. Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine 2000; 12: 110-9.
17. Brinkman BM, Giphart MJ, Verhoef A, Kaijzel EL, Verweij CL. Relevance of the tumor necrosis factor alpha -308 promoter polymorphism in TNF- alpha gene regulation. J Inflamm 1996; 46: 32-41.
18. Karimi M, Goldie LC, Cruickshank MN, Moses EK, Abraham LJ. A critical assessment of the factors affecting reporter gene assays for promoter SNP function: a reassessment of -308 TNF- polymorphism functions using a novel integrated reporter system. Eur J Human Genet 2009; 17: 1454-62.
19. Wilson A, Symons J, McDowell L, Duff G. Effects of a polymorphism in the human tumor necrosis factor promoter on transcriptional activation. PNAS 1997; 94: 3195-9.
20. Skoog T, Kallin B, Boquist S, Nillson J, Hamsten A.Acommon functional polymorphism in the promoter region of the tumour necrosis factor-α gene associated with reduced circulating levels of TNF-α. Human Mol Gen 1999; 8: 1443-9.
21. Wennberg P, Nordstrom P, Lorentzon R, Lerner U, Lorentzon M. TNF-alpha gene polymorphism and plasma TNF-alpha levels are related to lumbar spine bone area in healthy female Caucasian adolescents. Eur J Endocrinol 2002; 146: 629-34.
22. Kubota T, McNamara D, Wang J, et al. Effects of TNF- gene polymorphisms on patients with congestive heart failure. Circulation 1998; 97: 2499-501.
23. Ito M, Takahashi H, Fuse K, et al. Polymorphisms of tumor necrosis factor-alpha and interleukin-10 genes in Japanese patients with idiopathic dilated cardiomyopathy. Jpn Heart J 2000; 41: 183-91.
24. Mira JP, Cariou A, Grall F, et al. Association of TNF-2, a TNFalpha promoter polymorphism, with septic shock susceptibility and mortality. JAMA 1999; 282: 561-8.
25. Cuchacovich M, Ferreira L, Aliste M, et al. TNF-alpha levels and influence of -308 TNF-α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rhumatol 2006; 35: 435-40.
26. Fijen JW, Tulleken JE, Hepkema BG, Zijlstra JG. The influence if TNF- and IL-10 gene promoter polymorphism on the inflammatory response in experimental human endotoxinemia. CID 2001; 33: 1601-3.
27. Tang G, Huang S, Yien H, Chen W, WU W, Lee Y. TNF- gene polymorphism and septic shock in surgical infection. Crit Care Med 2000; 28: 2733-6.
28. Sharma S, Ghosh B, Sharma SK. Association of TNF- polymorphisms with sarcoidosis, its prognosis and tumour necrosis factor (TNF-)-levels in Asian Indians. Clin Exp Immunol 2007; 151: 251-9.
29. Kovar F, Marsik C, Cvitko T, Wagner O, Jilma B, Endler G. The tumor necrosis factor alpha -308G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia. Shock 2007; 27: 238-41.
30. Gordon AC, Lagan AL, Aganna E, et al. TNF- and TNF-R polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes Immun 2004; 5: 631-40.
31. Appoloni O, Dupont E, Vandercruys M, Andriens BS, Duchateau J, Vincent JL. Association of TNF-alpha -2 allele with plasma levels and mortality from septic shock. Am J Med 2001; 110: 486-8.
32. González S, Rodrigo L, Martínez-Borra J, et al. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol 2003; 98: 1101-6.
33. Bhushan B, Guleria R, Anoop misra, Kalpana Luthra, Naval K. Vikram. TNF-alpha gene polymorphism and TNF-alpha levels in obese Asian Indians with obstructive sleep apnea. Respiratory Medicine 2009; 103: 386-92.
34. Haddy N, Sass C, Maumus S, Marie B, Lambert D, Viskivis S. Biological variations, genetic polymorphisms and familial ressemblence of TNF-alpha concentrations: STANISLAS cohort. Eur J Hum Gen 2005; 13: 109-17.
35. Huizinga T, Westendorp R, Bollen E, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunology 1997; 49: 149-53.
36. Turner DM, Grant SC, Lamb WR, et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation 1995; 60: 1113-7.
37. de Jong BA,Westendorp RG, Bakker AM, Huizinga TWJ. Polymorphisms in or near tumour necrosis factor gene do not determine levels of endotoxin-induced TNF- production. Genes Immun 2002; 3: 25-9.
38. Westendorp R, Langermans AM, Huizinga T, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-3.
39. Louis E, Piron A, Roland S, et al. Tumour necrosis factor gene polymorphism influences TNF-α production in LPS-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 401-6.
40. Heesen M, Kunz D, Merk HF, Bloemeke B. Linkage disequilibrium between tumor necrosis factor -308G/A promoter and TNF-beta NcoI polymorphisms: association with TNF-alpha response of granulocytes to endotoxin stimulation. Crit Care Med 2004; 32: 1431-3.
41. Pachman L, Liotta-Davis M, Hong D, Randal T. TNF-308AA allele in dermatomyositis. Association with increased production of TNF-, disease duration and pathological calcifications. Arthritis Rheum 2000; 43: 2368-77.
42. Somoskovi A, Zissel G, Seitzer U, Gerdes J, Schlaak M, Mulller J. Polymorphisms at position -308 in the promoter region og the TNF- and in the first intron of the TNF-beta genes and spontaneous and LPS-induced TNF-alpha release in sarcoidosis. Cytokine 1999; 11: 882-7.
43. Mycko M,Kowalski W, Kwinkowski M, et al. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxinalpha. J Neuroimmunol 1998; 84: 198-206.
44. Fernandes H, Koneru B, Fernandes N, Hameed M, Cohen M, S Cohen. Investigation of promoter polymorphisms in the TNF- and IL-10 genes in liver transplant patients. Transplantation 2002; 73: 1886-91.
45. Huang DR, Pirskanen R, Matell G, Lefvert AK. Tumour necrosis factor-a polymorphism and secretion in myasthenia gravis. J Neuroimmunol 1999; 94: 165-71.
46. Bouma G, Crusius BA, Oudkerk P, Kolkman JJ, Pena AS. Secretion of TNF- alpha and lymphotoxine alpha in relation to polymorphisms in the TNF- genes and HLA-DR alleles. Scand J Immunol 1996; 43: 456-63.
47. Pociot F, Alfonso S, Compasso S, Scorza P, Richiardi PM. Functional analysis of a new polymorphism in the human TNF-a gene promoter. Scand J Immunol 1995; 42: 501-4.
48. Hoffmann S, Stanley E, Cox ED, et al. Association of cytokine polymorphic inheritance and in vitro production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001; 72: 1444-50.
49. Billolikar H, Rosenthal M, Davles JC, Henderson DC, Balfour-Lynn IM. TNF- gene polymorphisms and childhood wheezing. Eur Resp J 2005; 26: 637-46.
50. Tarkowski E, Liljeroth AM, Nilsson A, et al. TNF- gene polymorphism and its relation to intracerebral production of TNF-alpha and TNF-beta in AD. Neurology 2000; 54: 2077-81.
51. Hernandez-Guerrero C, Monzon-Bordonaba F, Jimenez-Zamudio L, et al. In-vitro secretion of proinflammatory cytokines by human amniochorion carrying hyperresponsive gene polymorphisms of tumour necrosis factor-alpha and interleukin-beta. Mol Hum Reproduction 2003; 9: 625-9.
52. Sharma S, Sharma A, Kumar S, Sharma K, Ghosh B. Association of TNF- Haplotypes with asthma, serum IgE levels, and correlation with serum TNF-alpha levels. Am J Respir Cell Mol Biol 2006; 35: 488-95.
53. Guis S, Balandraud N, Bouvenot J, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007; 57: 1426-30.
54. Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNFagents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008; 17: 3532-8.
55. Pavy S, Toonen E, Miceli-Richard C, et al. Tumour necrosis factor alpha -308G/A polymorphism is not associated with response to anti-TNF-α medication in patients with rheumatoid arthritis: systematic review and metaanalysis. Ann Rheum Dis 2010; 69: 1022-8.
56. Niewold T, Kariuki S, Morgan G, Pachman L. Elevated serum interferon-alpha activity in juvenile dermatomyositis: association with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009; 60: 1815-24.